China Universal Asset Management Company’s Inovio Pharmaceuticals INO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-574
Closed -$2.68K 456
2023
Q3
$2.68K Buy
574
+287
+100% +$1.58K ﹤0.01% 423
2023
Q2
$1.54K Buy
287
+5
+2% +$40 ﹤0.01% 439
2023
Q1
$2.77K Buy
282
+71
+34% +$1.21K ﹤0.01% 421
2022
Q4
$3.96K Buy
211
+16
+8% +$363 ﹤0.01% 322
2022
Q3
$4K Buy
+195
New +$4.99K ﹤0.01% 300

Other funds holding INO

China Universal Asset Management Company's INO Position: Q4 2023 in Review

China Universal Asset Management Company sold out of Inovio Pharmaceuticals (INO) in Q4 2023, closing a stake of 574 shares — an estimated $2.68K sold.

China Universal Asset Management Company first reported a position in INO in Q3 2022 and held it in 5 quarters. The position peaked at $4K in Q3 2022. 113 funds tracked by Wall St. Rank hold INO as of Q4 2023.

  • China Universal Asset Management Company reported no remaining Inovio Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • China Universal Asset Management Company sold 574 Inovio Pharmaceuticals shares in Q4 2023, an estimated $2.68K.
  • China Universal Asset Management Company first reported a position in Inovio Pharmaceuticals in Q3 2022 and held it in 5 quarters.
  • China Universal Asset Management Company's Inovio Pharmaceuticals position peaked at $4K in Q3 2022.
  • 113 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q4 2023.

Based on China Universal Asset Management Company's 13F filing for Q4 2023, filed 24 Jan 2024.